1. Scrip
  2. >>R&D

TxCell Plans First In Man Trial Of Regulatory T-Cells

 
• By Mike Ward

Stéphane Boissel, CEO of TxCell, discusses the company's plans to advance its lead next-generation regulatory T-cell candidate into human studies, after having switched to a new platform, in a video interview with Scrip.

Video interview
TxCell's CEO talks to Scrip

Having completed a Phase I/Iia study of Ovasave, a drug candidate from its first generation non-modified antigen-specific regulatory T-cells (Tregs), TxCell expects to start a first in man study of a candidate from its next generation Treg platform in 2018. The company switched emphasis from its ASTrIA platform to the ENTrIA platform two years ago after coming up against some manufacturing issues.

ENTrIA is a platform that uses Tregs engineered with a chimeric antigen receptor (CAR). The company has more than 10 CAR-Treg development programs focusing on diseases such as lupus nephritis, bullous pemphigoid, multiple sclerosis and Crohn’s disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.